oxysterol binding protein like 9Genealiases: ORP-9 · ORP9
Q-omics provides the consensus-scored OSBPL9 profile across patient tissues and cancer cell-line models. OSBPL9 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, OSBPL9 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, OSBPL9 RNA expression shows 20,530 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, HNSC, and UVM as cancer lineages where OSBPL9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OSBPL9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OSBPL9 survival associations across molecular data types. OSBPL9 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OSBPL9 RNA expression–survival associations across cancer types. High OSBPL9 expression shows unfavorable associations in KICH, LGG, STAD and SKCM, but favorable associations in KIRC and ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for OSBPL9 RNA expression.
This table summarizes OSBPL9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OSBPL9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OSBPL9 shows lower tumor expression in KICH, THCA, BRCA and KIRC and higher tumor expression in HNSC and BLCA. The HNSC box plot shows higher OSBPL9 RNA expression in tumor versus normal tissue (log2 FC = +1.141, t-test p < 0.001).
This table shows molecular features associated with OSBPL9 in patient tissues and cancer cell lines. In patient samples, OSBPL9 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, OSBPL9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
